U.S. markets closed

XpresSpa Group, Inc. (XSPA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6200+0.0600 (+3.85%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.5600
Open1.6100
Bid1.6200 x 3100
Ask1.6300 x 3000
Day's Range1.3800 - 1.6500
52 Week Range0.1500 - 8.8200
Volume7,931,353
Avg. Volume13,382,856
Market Cap152.323M
Beta (5Y Monthly)2.38
PE Ratio (TTM)N/A
EPS (TTM)-3.0120
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • XpresSpa Group Signs Contract with Port of Seattle for an XpresCheck™ COVID-19 Pop-Up Testing Facility at Seattle-Tacoma International Airport
    GlobeNewswire

    XpresSpa Group Signs Contract with Port of Seattle for an XpresCheck™ COVID-19 Pop-Up Testing Facility at Seattle-Tacoma International Airport

    First XpresCheck Testing Facility on the West Coast Expected to Commence Operations by mid-MarchSEATTLE, March 04, 2021 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced that it has signed a contact with the Port of Seattle for an XpresCheck™ COVID-19 pop-up testing facility at Seattle-Tacoma International Airport (SEA). This is the Company’s first testing facility on the West Coast and it is expected to be fully-operational by mid-March. XpresCheck will be building a pop-up facility pre-security in Baggage Claim near Carousel 9. It will host eight separate testing rooms with an anticipated capacity to administer over 500 tests per day. COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test. Doug Satzman, XpresSpa CEO, stated, “We are excited to be launching XpresCheck at SEA Airport as it marks our first COVID-19 testing facility on the West Coast. Additionally, we are proud to be a trusted partner of Hawaiian Airlines and the state of Hawaii as several direct flights to Hawaii originate at SEA. This helps to make pre-travel testing accessible and seamless for passengers taking a long-awaited Hawaii vacation.” Satzman continued, “Expanding the XpresCheck brand enables us to provide convenient, reliable COVID-19 testing and related medical services across a greater number of airports and further supports our long-term goal of becoming the leading brand in the Travel Health and Wellness category.” About XpresSpa Group, Inc. XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 23 airports globally. Through its XpresTest, Inc. subsidiary, the Company provides COVID-19 screening and testing under the XpresCheck™ brand at seven locations in six airports: Denver International Airport, JFK International Airport, Logan International Airport (2), Newark Liberty International Airport, Phoenix Sky Harbor International Airport, and Salt Lake City International Airport. To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com. Twitter: @xprescheck and Instagram: @realxprescheck Forward-Looking Statements Forward-Looking Statements This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof. Investor Relations:ICRRaphael Grossir@xpresspagroup.com(203) 682-8253 Media:Julie FergusonJulie@jfprmedia.com(312) 385-0098

  • XpresSpa Group Signs Contract with Metropolitan Washington Airports Authority for XpresCheck™ COVID-19 Testing Facilities at Dulles International Airport and Reagan National Airport
    GlobeNewswire

    XpresSpa Group Signs Contract with Metropolitan Washington Airports Authority for XpresCheck™ COVID-19 Testing Facilities at Dulles International Airport and Reagan National Airport

    Both Locations Expected to Commence Operations by Mid-MarchWASHINGTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced that it has signed a contract with Metropolitan Washington Airports Authority for XpresCheck™ COVID-19 Testing Facilities at Dulles International Airport and Reagan National Airport. Both of these locations are expected to be fully operational by mid-March. At Dulles International Airport, XpresCheck will be building a pop-up facility located in the Main International Terminal, pre-security. This facility will host nine separate testing rooms with an anticipated capacity to administer over 500 tests per day. COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test. At Reagan National Airport, XpresCheck will be building a pop-up facility in their existing XpresSpa location at National Hall, pre-security. This facility will host four separate testing rooms with an anticipated capacity to administer over 300 tests per day. COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test. Doug Satzman, XpresSpa CEO, stated, "We are excited to be expanding XpresCheck to the metro Washington DC region by opening at both Dulles International and Reagan National next month. We recognize the important role our COVID-19 testing facilities play in supporting domestic and international air travel by ensuring airport employees and travelers feel safe and confident when traveling through our nation’s capital.” About XpresSpa Group, Inc. XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 23 airports globally. Through its XpresTest, Inc. subsidiary, the Company provides COVID-19 screening and testing under the XpresCheck™ brand at eight locations in six airports: Denver International Airport, JFK International Airport, Boston Logan International Airport (2), Newark Liberty International Airport (2), Phoenix Sky Harbor International Airport, and Salt Lake City International Airport. To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com. Twitter: @xprescheck and Instagram: @realxprescheck Forward-Looking StatementsThis press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof. Investor Relations:ICRRaphael Grossir@xpresspagroup.com (203) 682-8253 MediaJulie FergusonJulie@jfprmedia.com(312) 385-0098

  • XpresSpa Stock Has a New Bull on Wall Street
    TipRanks

    XpresSpa Stock Has a New Bull on Wall Street

    NYC-based XpresSpa Group (XSPA) operates spa services in airports, catering to jet-setting business travelers as they fly around the U.S. And you might think that this is about the worst business model imaginable to be in, in the middle of a pandemic when folks are avoiding walk-in, hands-on services like spa treatments -- and avoiding flying, period. You might think that… but H.C. Wainwright analyst Scott Buck begs to differ. The reason Buck thinks differently about XpresSpa, as he explains in a note out Tuesday, is because in the middle of this pandemic, the company is "pivoting" and transforming its spa-centric business into "a more comprehensive travel health and wellness store model which includes medical testing." And medical testing in airports is very relevant to our current pandemic. Buck explains that the company's new XpresCheck medical testing service, which the company has been rolling out over the last several months, is now up and running at six U.S. airports. It could "potentially" reach as many as 60 -- twice as many airports as the company previously maintained spa locations in. As air travel "normalizes over the next six-to-12 months," predicts Buck, the provision of "medical testing, including for COVID-19" services is likely to transform XpresSpa into "a leading airport focused health and wellness provider." COVID-19, observes the analyst in what may be the understatement of the decade, "is likely to permanently change travel habits," and airports are looking for new ways to ensure travelers are healthy enough to travel, and safeguard national (and international) populations from disease spread. Already, notes Buck, countries like the Netherlands and U.S. states like Hawaii require that any traveler who wishes to deplane at their airports be able to show proof of a negative COVID-19 PCR test taken within 72 hours of departure. And the analyst sees this as just the start of a trend that will see more U.S. states, and more international countries, adopt similar requirements. From six locations today, Buck predicts XpresSpa will grow to service 30 airports by the end of 2022, en route to doubling again, and growing at the rate of three to four new locations per quarter. Moreover, larger airports may be big enough to support more than one location per airport, increasing the company's growth potential. At the same time, Buck sees the company's estimated $90 million in cash on hand should lasting long enough to support this expansion for at least the next two years, before it needs to raise more cash, because the company is burning through cash at the rate of only about $7 million to $9 million per quarter. Profits-wise, Buck admits that XpresSpa is currently unprofitable -- and likely to remain so through at least 2021. By 2022, however, Buck sees cash flow turning positive, and "adjusted EBITDA" as well. So while for the time being, Buck can only value the company on its revenues (positing a 3.5x fiscal 2022 revenue valuation), in just a year or two, investors may finally be able to hang a P/E ratio on this one. To this end, Buck initiated coverage of XpresSpa stock with a Buy rating and a $3.50 per share price target. This target implies ~30% upside from the current share price of $2.70. (To watch Buck's track record, click here) Penny stocks tend to fly under the radar, and XSPA is one of those. Buck's is the only recent analyst review of this company, and it is decidedly positive. (See XSPA stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.